Home » Topics » Cancer, BioWorld Science

Cancer, BioWorld Science
RSS

NMBS-2: a selective and potent HPK1 inhibitor for enhancing antitumor immunity

Oct. 29, 2020

AUR-102: a potent and selective CDK7 inhibitor for cancer treatment

Oct. 29, 2020

Recruitment completed in phase III FORTRESS study of balixafortide

Oct. 29, 2020

Australian regulatory authorities approve phase I study of APL-1501

Oct. 29, 2020

CDK2/cyclin E inhibitors synthesized by Incyte

Oct. 29, 2020

Aligos Therapeutics presents new PRMT5 inhibitors

Oct. 29, 2020

Drugging resistant androgen receptors

Oct. 29, 2020

Novel selective TRK degraders effectively reduce TPM3-TRKA fusion protein levels

Oct. 28, 2020

Apollomics reports phase I data for APL-101

Oct. 28, 2020

First-in-human data presented for TPX-0022

Oct. 28, 2020

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 16, 2026.
AAIC 2026: Age of amyloid is being joined by time of tau
BioWorld
The Alzheimer’s Association International Conference (AAIC) is the world’s biggest dementia conference. And at the AAIC 2026 meeting, there is big buzz around...
Celia trial: data strong, analysts skeptical
BioWorld
Tuesday brought what was arguably the most anticipated presentation of the 2026 Alzheimer’s Association International Conference when Catherine Mummery, head of...
News in brief
BioWorld Asia
BioWorld Asia briefs for July 14, 2026
GABA signaling linked to immune resistance in some tumors
BioWorld
Certain cancers that contain organized clusters of immune cells known as tertiary lymphoid structures (TLS) do not respond to treatment as well as expected. Even...